Who are Budecort Aqua's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qvar (100 mcg), Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Monotherapy of medium dose ICS, Inhaled Fluticasone Propionate, Usual Care Inhaled Glucocorticosteroids, FLOVENT 500mcg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/budecort-aqua.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Budecort Aqua — Competitive Intelligence Brief

Budecort Aqua (Budecort Aqua) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid (ICS). Area: Respiratory / Pulmonology.

phase 3 Inhaled corticosteroid (ICS) Glucocorticoid receptor (GR) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Budecort Aqua (Budecort Aqua) — Eurofarma Laboratorios S.A.. Budecort Aqua is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Budecort Aqua TARGET	Budecort Aqua	Eurofarma Laboratorios S.A.	phase 3	Inhaled corticosteroid (ICS)	Glucocorticoid receptor (GR)
Qvar (100 mcg)	Qvar (100 mcg)	Research in Real-Life Ltd	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Orion Corporation, Orion Pharma	marketed	Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)	Glucocorticoid receptors and β2-adrenergic receptors
Monotherapy of medium dose ICS	Monotherapy of medium dose ICS	Ajou University School of Medicine	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor
Inhaled Fluticasone Propionate	Inhaled Fluticasone Propionate	VA Office of Research and Development	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor
Usual Care Inhaled Glucocorticosteroids	Usual Care Inhaled Glucocorticosteroids	AstraZeneca	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor (GR)
FLOVENT 500mcg	FLOVENT 500mcg	GlaxoSmithKline	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid (ICS) class)

Ajou University School of Medicine · 1 drug in this class
AstraZeneca · 1 drug in this class
Eurofarma Laboratorios S.A. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Organon and Co · 1 drug in this class
Research in Real-Life Ltd · 1 drug in this class
SkyePharma AG · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Budecort Aqua — Competitive Intelligence Brief. https://druglandscape.com/ci/budecort-aqua. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab